Optimizing cardiovascular disease risk screening in a low-resource setting: cost-effectiveness of program modifications in Sri Lanka modelled with nationally representative survey data
Open Access
- 15 September 2023
- journal article
- research article
- Published by Springer Nature in BMC Public Health
- Vol. 23 (1) , 1-13
Abstract
Background: While screening for cardiovascular disease (CVD) risk can help low-resource health systems deliver low-cost, effective prevention, evidence is needed to adapt international screening guidelines for maximal impact in local settings. We aimed to establish how the cost-effectiveness of CVD risk screening in Sri Lanka varies with who is screened, how risk is assessed, and what thresholds are used for prescription of medicines. Methods: We used data for people aged 35 years and over from a 2018/19 nationally representative survey in Sri Lanka. We modelled the costs and quality adjusted life years (QALYs) for 128 screening program scenarios distinguished by a) age group screened, b) risk tool used, c) definition of high CVD risk, d) blood pressure threshold for treatment of high-risks, and e) prescription of statins to all diabetics. We used the current program as the base case. We used a Markov model of a one-year screening program with a lifetime horizon and a public health system perspective. Results: Scenarios that included the WHO-2019 office-based risk tool dominated most others. Switching to this tool and raising the age threshold for screening from 35 to 40 years gave an incremental cost-effectiveness ratio (ICER) of $113/QALY. Lowering the CVD high-risk threshold from 20 to 10% and prescribing antihypertensives at a lower threshold to diabetics and people at high risk of CVD gave an ICER of $1,159/QALY. The findings were sensitive to allowing for disutility of daily medication. Conclusions: In Sri Lanka, CVD risk screening scenarios that used the WHO-2019 office-based risk tool, screened people above the age of 40, and lowered risk and blood pressure thresholds would likely be cost-effective, generating an additional QALY at less than half a GDP per capita.Keywords
Funding Information
- Direktion für Entwicklung und Zusammenarbeit (400640_160374, 400640_160374)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (400640_160374, 400640_160374)
- Institute for Health Policy Public Interest Research Fund (PIRF-2018-02, PIRF-2018-02)
This publication has 50 references indexed in Scilit:
- Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular DiseaseJAMA, 2015
- Quantifying the Utility of Taking Pills for Cardiovascular PreventionCirculation: Cardiovascular Quality and Outcomes, 2015
- Thresholds for the cost–effectiveness of interventions: alternative approachesBulletin of the World Health Organization, 2014
- Patient-Accessible Tool for Shared Decision Making in Cardiovascular Primary PreventionCirculation, 2014
- 5-year survival and rehospitalization due to stroke recurrence among patients with hemorrhagic or ischemic strokes in SingaporeBMC Neurology, 2013
- How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?Current Atherosclerosis Reports, 2012
- Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trialsQJM: An International Journal of Medicine, 2010
- Long-Term Trends in the Incidence of Heart Failure After Myocardial InfarctionCirculation, 2008
- General Cardiovascular Risk Profile for Use in Primary CareCirculation, 2008
- Accounting for future costs in medical cost-effectiveness analysisJournal of Health Economics, 1997